clinical trial · NCT06517888
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Akouos, Inc.·phase2·recruiting·n = 27
Vestibular SchwannomaAAVAnc80-antiVEGF via Akouos Delivery Device
brief summary
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
started
Jan 17, 2025
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Apr 6, 2026
official title
A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol